Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
DS-1103 by Integral Molecular for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
DS-1103 is under clinical development by Integral Molecular and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...